FOSUN HEALTH Logo

Vestibular Schwannoma Overview

catalogue

Vestibular Schwannoma Overview

Vestibular Schwannoma Overview

A vestibular schwannoma — still widely called an acoustic neuroma — does not arise from the brain. It arises from the Schwann cells that sheathe the vestibular half of the eighth cranial nerve, the nerve that carries hearing and balance, where that nerve runs through a narrow canal in the bone of the skull base. It is benign: it does not spread, and many of these tumours grow slowly or not at all. What makes it a distinct problem is where it lives — a bony passage with no room to spare — because a tumour there compresses the very fibres that carry sound, which is why a one-sided, gradually progressive hearing loss is usually the first thing to appear.

Vestibular Schwannoma Overview
  • it does not spread through the body; the risks come from pressure in a narrow space

  • a one-sided, progressive hearing loss is the commonest first sign

  • size, growth on successive scans, and the hearing on that side decide the plan

  • from complete records to a personalized MDT plan

What a vestibular schwannoma is

The nerve of hearing and balance — the eighth cranial nerve — has two halves: the cochlear half, which carries sound, and the vestibular half, which carries signals about head position and movement. Like the nerves of the body, it is insulated by cells called Schwann cells. A vestibular schwannoma is a benign overgrowth of those cells on the vestibular half. It usually begins at the inner end of the bony canal that carries the nerve from the inner ear towards the brain, and it grows from there into the space at the side of the brainstem called the cerebellopontine angle.

Three features of that location explain almost everything about the condition. The first is that the canal leaves no room to spare. A tumour growing inside it presses on the nerve fibres travelling alongside it long before it presses on the brain, and the fibres that fail first are the ones that carry sound. This is why a hearing loss in one ear, creeping up over months or years, is the usual first sign — and why the loss is often noticed on the telephone, or when one ear is blocked, rather than in a doctor's office.

The second is that it is a tumour of the nerve, not of the brain. It is benign, it does not invade the brain tissue, and it does not spread anywhere else in the body. The problems it causes are problems of compression — of the hearing nerve first, then of the facial nerve which runs through the same canal, then of the nerve of facial sensation, and only in large tumours of the brainstem itself. That is also why treatment is judged by what it protects: the facial nerve, the hearing that remains, and the structures of the brainstem.

The third is that its growth is slow and, in any individual, unpredictable. Some tumours never grow measurably; some grow a few millimetres over years; a smaller share grows faster. No test performed at diagnosis predicts with certainty which will do which — which is why observation with scheduled scans is a real treatment option here rather than a delay, and why any comparison of scans is only as good as the earlier images.

What kind of tumour it is, and where it grows

Vestibular schwannomas are described along three axes, and a patient will usually be told all three:

  • By nature. It is a benign tumour of Schwann cells — in WHO terms a grade 1 schwannoma — and malignant change is exceedingly rare. The clinical question is never whether it is a cancer but what it is pressing on and whether it is growing.
  • By number and origin. The great majority are single and sporadic — occurring by chance, with no inherited cause and no implication for relatives. Bilateral tumours — one on each hearing nerve — are the hallmark of the inherited condition neurofibromatosis type 2, and their discovery sets in motion a genetic assessment and a different, lifelong surveillance programme.
  • By position — contained in the canal. An intracanalicular tumour lies entirely within the internal auditory canal. It is the earliest stage, often the smallest, and the one in which hearing loss or one-sided tinnitus may be the only finding.
  • By position — extending into the posterior fossa. As the tumour enlarges it passes out of the canal into the cerebellopontine angle, where it may press on the brainstem, the facial nerve, the nerve of facial sensation, and eventually the pathways of the cerebellum. Position beyond the canal is what brings imbalance, facial numbness and, in the largest tumours, headache and raised pressure.
  • By the tissue itself. No biopsy is needed — the diagnosis is made on MRI. Tissue is examined in the uncommon event that the tumour is removed as treatment, and it confirms the diagnosis rather than revealing a grade that changes the plan.

Size, growth and hearing classification

This tumour is not staged in the way cancers are. Three measures do the work instead — how large the tumour is, whether it is growing, and what the hearing is doing:

Measure In plain terms How it is used
Intracanalicular The tumour lies entirely within the canal of the hearing nerve (often reported as Koos grade I) Symptoms are usually confined to the ear; both observation and focused radiation are common choices
Small The tumour has begun to enter the space beside the brainstem but remains small (Koos grade II) All three options — observation, radiation, surgery — are usually still on the table
Medium The tumour occupies the cerebellopontine angle and may indent the brainstem (Koos grade III) Growth and symptoms push towards treatment; hearing preservation becomes less likely to succeed
Large The tumour compresses the brainstem or cerebellum (Koos grade IV) Treatment rather than observation; the facial nerve and the brainstem dominate the planning
Growth The change measured between successive scans, compared like with like The single most influential finding for a tumour that is causing little: quiet tumours can be watched, growing tumours move towards treatment
Hearing class What the affected ear can still do — how loud sounds must be, and how clearly words are understood Shapes the choice between approaches; hearing that is still useful changes what is worth attempting

The practical point is that size alone decides less than it appears to. A small tumour that is growing in a patient with useful hearing is treated, and a larger tumour that has been quiet for years in a patient with no useful hearing on that side may legitimately be watched. The three measures are read together, and the patient's own priorities — which hearing means what to them, and what they are willing to trade — belong in that reading.

The genetic findings, and when they matter

Molecular and genetic testing here is not about choosing a drug. It is about recognising the uncommon patient whose tumour is part of an inherited condition, because that changes the follow-up for life:

Finding What it is How it changes management
NF2 alteration A change in the NF2 gene, which produces a protein called merlin that regulates these cells; found in the tumour cells of schwannomas generally When it reflects the inherited condition, it sets a lifelong surveillance programme for both sides and for the rest of the nervous system
Bilateral tumours A schwannoma on each hearing nerve The hallmark of neurofibromatosis type 2; genetic assessment is offered rather than optional
Young age or family history A single tumour at an unusually young age, or schwannomas in relatives A reasonable reason to ask for genetic assessment, since inherited forms announce themselves early
Other nerve schwannomas Schwannomas elsewhere in the body, particularly multiple ones Raises the question of the rarer schwannomatosis conditions, which have their own genetic assessment
Sporadic unilateral tumour A single tumour in an adult in midlife with no family history Genetic testing rarely changes anything; its absence from the plan is not a gap

Two conclusions follow. First, for the great majority — a single tumour in an adult in midlife — no genetic test is needed and none changes the plan. Second, in the situations listed above, testing is worth doing properly, because a diagnosis of neurofibromatosis type 2 brings with it scheduled imaging of both sides, surveillance of the spine and other nerves, and information that matters to relatives. Asking which situation you are in is a reasonable question to put to the team.

Why patients come to China for vestibular schwannoma care

The care of a vestibular schwannoma is decided by a small number of capabilities that have to work together, and the balance between them is what the treatment consists of: a decision to treat or to watch, a choice between radiation and surgery, and the protection of the facial nerve and the hearing throughout.

  • Imaging on the right protocol — thin-slice contrast MRI through the internal auditory canal, since small intracanalicular tumours are easily missed on a routine brain study, and comparison with earlier scans is what the whole decision rests on.
  • Audiology that measures what matters — pure tone and speech discrimination testing on both sides, recorded before treatment, because the hearing on the affected side is one of the three findings that decides the plan.
  • Precision radiation when the tumour is suitable — stereotactic radiosurgery delivered in a single session for small and medium tumours, with the head held exactly still and the dose shaped to the tumour.
  • Surgery planned around the facial nerve — skull base approaches chosen by size and by hearing status, with monitoring of the facial nerve throughout the operation and the aim of removing the tumour while preserving movement.
  • Hearing and balance rehabilitation — devices and strategies for one-sided hearing loss, tinnitus management and balance retraining, which are treatment in their own right rather than afterthoughts.
  • One written plan, reviewed together — neurosurgery, radiation oncology and audiology reading the same scans and the same audiograms, so that the three findings are weighed once rather than argued between departments.

Because the treatment of this tumour is often a decision followed by years of scheduled scans rather than a single episode, patients who live elsewhere commonly have the diagnosis reviewed and the radiation or the operation performed in China, then return home with a written schedule for the imaging and the hearing tests that follow. The records that make this workable are the MRI images and reports with dates — every scan, not only the latest — the audiograms on both sides, the operative or radiotherapy record if treatment has been given, and the current medication. Send those, and the written assessment is returned within 48 hours of the file being complete.

Frequently Asked Questions

Is a vestibular schwannoma cancer?

No. It is a benign tumour of the insulating cells on the nerve of hearing and balance. It does not spread to other parts of the body, and it does not invade the brain the way a malignant tumour does — it pushes structures aside. That is why the words used about it are about pressure and compression rather than about spreading, and why treatment is judged by what it protects — the facial nerve, the hearing that remains, and the brainstem — rather than by margins and stages. Malignant change is exceedingly rare and is not the question the team is trying to answer.

Will I lose my hearing on that side?

The hearing is often already affected by the time the tumour is found, and how much of it can be kept depends chiefly on two things: how much hearing there was to begin with, and what treatment is chosen. Hearing that is still useful changes what is worth attempting. Observation itself does not worsen hearing beyond what the tumour is doing; radiation aims to stop growth while preserving the hearing that remains; surgery varies by approach, and some approaches involve accepting the loss of hearing on that side as the price of removing the tumour. This is a question to ask early and explicitly, with the audiogram in front of you.

Why would we watch a tumour instead of removing it?

Because many of these tumours grow slowly or not at all, and because operating in this canal carries real risks to the facial nerve and to the hearing that no one should take for a tumour that is doing nothing. Observation is therefore an established option rather than a delay — provided it comes with a schedule. The scans are compared with the earlier studies, growth between scans moves the tumour towards treatment, and new symptoms are reported rather than waited out. A decision to observe should leave you knowing when the next scan is and what would end the watching.

Is it caused by mobile phone use?

No link has been established. Because the phone is held against the ear, the question has been studied for years, and the studies have not shown that phone use causes these tumours. The one clearly established risk factor is the inherited condition neurofibromatosis type 2, in which tumours arise on both hearing nerves; previous radiotherapy to the head at therapeutic doses is a rare further association. For the great majority of patients no cause can be identified, and nothing they did — or failed to do — brought the tumour about.

Send the imaging and the hearing tests, get a written plan

Upload the MRI images and reports with dates — every scan, not only the latest — the audiograms on both sides, the operative or radiotherapy record if treatment has been given, and the current medication. Our neurosurgery, radiation oncology and audiology team will return a written assessment within 48 hours of the file being complete, setting out whether the tumour can be observed, treated with radiation or removed, and what each of those options would mean for the hearing and the facial nerve.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*